Results 41 to 50 of about 28,373 (234)
Drug–drug interaction profile of ritlecitinib as perpetrator and victim through cytochrome P450
British Journal of Clinical Pharmacology, EarlyView.Aims To assess the effect of a potent cytochrome P450 (CYP) 3A inhibitor and CYP inducer on the pharmacokinetics of ritlecitinib, a JAK3/TEC family kinase inhibitor, and assess the effect of ritlecitinib on the pharmacokinetics of CYP substrates (midazolam, efavirenz, tolbutamide, caffeine and oral contraceptives [ethinyl oestradiol and levonorgestrel])
Vivek S. Purohit +6 more
wiley +1 more source
Temporal triangular alopecia: A rare entity
Clinical Dermatology Review, 2023 Congenital triangular alopecia (CTA) presents as a localized nonscarring patch of alopecia. It is likely to be confused with alopecia areata. The case is being reported to increase awareness and familiarize clinicians about this rare condition of CTA ...
Sonia P Jain +2 more
doaj +1 more source
Comparison of oral prednisolone pulse therapy with intravenous methylprednisolone pulse therapy in severe alopecia areata [PDF]
, 2013 Objective: To compare the efficacy of oral prednisolone pulse therapy in comparison to the intravenous methylprednisolone pulse therapy in treatment of severe alopecia areata. Patients and methods: In this interventional study, all patients with alopecia
Alborzi, A., Dehghan, A., Shahini, N.
core
COLLAB: A Global Survey of Clinical and Laboratory Assessment in Alopecia Areata by Hair Specialists
JEADV Clinical Practice, EarlyView.ABSTRACT Background Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used to treat AA. Objectives The aim was to assess variation in laboratory testing in patients with AA among hair experts internationally and to compare
Cathal O'Connor +39 more
wiley +1 more source
Acta Dermato-VenereologicaThe emergence of new systemic treatments for alopecia areata underscores the importance of estimating rates of potential treatment safety events among individuals with alopecia areata.
Sissel Brandt Toft Sørensen +7 more
doaj +1 more source
Janus Kinase Inhibitors in the Treatment of Alopecia Areata
Prague Medical Report, 2023 Alopecia areata is a disease of autoimmune origin which causes non scarring hair loss. The extent of alopecia varies from a small patch to complete scalp and body hair loss, which can have huge psychosocial impact for those affected. Treatment modalities
Athanasios J. Stefanis
doaj +1 more source
JEADV Clinical Practice, EarlyView.We present a case of a 31‐year‐old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis, who showed poor response to prior treatments. Following the initiation of a combination therapy with tofacitinib and methotrexate, significant improvements in joint pain and hair regrowth were observed.
Jan Nicolai Wagner +4 more
wiley +1 more source
Acta Dermato-VenereologicaOnline resources play a vital role in patient education, yet the readability of alopecia areata-related materials remained understudied. A thorough analysis of online alopecia areata-related materials across 5 languages was conducted using Google search.
Tomasz Skrzypczak +2 more
doaj +1 more source
Dermatology and Therapy, 2023 Background Numerous studies have indicated that alopecia areata is associated with a chronic systemic inflammation, which is considered as a risk factor for venous thromboembolism.
Anna Waśkiel-Burnat +9 more
doaj +1 more source
Retrospective review of diphencyprone in the treatment of alopecia areata [PDF]
, 2015 Contact immunotherapy with diphencyprone (DCP) is used to treat alopecia areata (AA). Its reported efficacy is variable, and individual response cannot be predicted.
Holmes, S., Lamb, R. C., Young, D.
core +1 more source